TargetBeta
CDH17
cadherin 17 · also HPT-1, cadherin · 7D cadherins
7 programs in company-led studies act on CDH17, from 7 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| AMT-676rule | Multitude Therapeutics | phase 2 | 22 running | – | the studies' text |
| Anti-CDH17 Antibody-drug Conjugate HS-20110 | Hansoh Pharmaceutical Group | phase 2 | 22 running | – | the company's pipeline |
| Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911rule | Mabwell (Shanghai) Bioscience | phase 2 | 22 running | – | NCIt |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | DualityBio | phase 2 | 11 running | – | NCIt |
| LM-350 | Sino Biopharmaceutical | phase 2 | 11 running | – | the company's pipeline |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 11 running | – | NCIt |
| Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rule | ArriVent BioPharma | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Colorectal Neoplasms, 2 programs
- Gastrointestinal Neoplasms, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026Anti-CDH17 Antibody-drug Conjugate HS-20110 · Hansoh Pharmaceutical Group · phase 2 · NCT06892379
- May 15, 2027AMT-676 · Multitude Therapeutics · phase 2 · NCT06400485
- Jul 2027Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911 · Mabwell (Shanghai) Bioscience · phase 2 · NCT07216560
- Mar 2028Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217 · ArriVent BioPharma · phase 1 · NCT07066657
- Jun 30, 2028LM-350 · Sino Biopharmaceutical · phase 2 · NCT07112222
- Jul 2028Anti-CDH17 Antibody-drug Conjugate YL217 · MediLink Therapeutics (Suzhou) · phase 1 · NCT06859762
- Dec 2028Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324 · DualityBio · phase 2 · NCT07263594
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.